Topics

OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi in Korea with Chong Kun Dang Pharmaceutical Corporation

12:04 EST 7 Nov 2019 | FinanzNachrichten

Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE), today announced a new licensing deal with Chong Kun Dang (CKD) Pharmaceutical Corporation for Tedopi, a combin...

Original Article: OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi in Korea with Chong Kun Dang Pharmaceutical Corporation

NEXT ARTICLE

More From BioPortfolio on "OSE Immunotherapeutics Announces Licensing Deal for Neoepitope Combination Tedopi in Korea with Chong Kun Dang Pharmaceutical Corporation"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...